Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients.
Tyrosine kinase inhibitors (TKIs) are used in different types of cancers due to their good profile of adverse reactions and their convenience in the oral administration. Some studies describe that certain TKIs are associated with changes in the glycemic profile of the patients. This study aims to determine if treatment with ITK affects to serum glucose levels in clinical practice. A retrospective study was carried out in 136 episodes (112 patients treated with sorafenib, sunitinib, imatinib, dasatinib, or nilotinib). The serum glucose levels were analyzed before treatment and after months 1, 2, 3, 6, 9, and 12 of treatment. Statistical analysis was completed with SPSS version 20 for Windows. There were significant differences in the serum glucose levels before treatment between diabetic and nondiabetic patients, but not between the average blood glucose readings before treatment and the average of the subsequent readings, once their treatment had begun. The results of this study do not reproduce the results of the literature since changes in the serum glucose levels have not been found in this sample of patients.